Quarterly report Q2/2025: Strong development in Sweden and increased international activity: Enzymatica AB

"During the second quarter, efforts to establish new partnership agreements intensified. ColdZyme's strong clinical evidence is generating significant global interest, but the path to attractive deals is complex – and requires patience, persistence, and precision. We are currently focused on identifying the right commercial partners, primarily within the EU, while also engaging in ongoing discussions with a number of global players in the over-the-counter common cold treatment category", says Claus Egstrand, CEO.  

LUND, Sweden, 17/07/2025 (informazione.news - comunicati stampa - scienza e tecnologia)

" says Claus Egstrand, CEO.  

The full report is available at https://www.enzymatica.com/investors/financial-reports/

Claus Egstrand, CEO, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com  

Enzymatica AB is headquartered in Lund and is listed on Nasdaq First North Growth Market. For more information, visit www.enzymatica.se.
Enzymatica's Certified Adviser is DNB Carnegie Investment Bank AB (publ).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/quarterly-report-q2-2025--strong-development-in-sweden-and-increased-international-activity,c4208114

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/quarterly-report-q22025-strong-development-in-sweden-and-increased-international-activity-enzymatica-ab-302507728.html